GSK’s Blenrep is the only B-cell maturation antigen (BCMA)-targeted antibody-drug conjugate for multiple myeloma, offering ...

GSK said on Thursday two combination therapies with its cancer drug, Blenrep, have received approval from British authorities ...

The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has authorised GSK’s Blenrep for treating multiple ...

GSK’s blood cancer drug Blenrep won regulatory approval in the U.K., marking the medicine’s return to the market after it was ...

The U.K.’s Medicines and Healthcare products Regulatory Agency (MHRA) on Thursday authorized GSK plc’s (NYSE:GSK) Blenrep.

GSK's Blenrep (belantamab mafodotin) has officially been approved by the UK's Medicines and Healthcare products Regulatory ...

GSK plc has announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has authorised Blenrep. In the UK, ...

GSK has secured the first regulatory approval for Blenrep since the antibody-drug conjugate’s global market withdrawal in 2022. | GSK has secured the first regulatory approval for Blenrep since the ...

GSK (GSK) plc announced the authorization of Blenrep by the Medicines and Healthcare products Regulatory Agency. “In the UK, Blenrep is ...

April 17 (Reuters) - GSK (GSK.L), opens new tab said on Thursday two combination therapies with its cancer drug, Blenrep, have received approval from British authorities for the treatment of a ...

Blenrep combo nearly tripled PFS to 36.6 months vs 13.4 months in DREAMM-7. Blenrep cut risk of death by 42% vs comparator in DREAMM-7 at 39.4-month median follow-up. Feel unsure about the market ...

In DREAMM-8, at a median follow-up of 21.8 months, the median PFS was not yet reached with the Blenrep combination compared to 12.7 months in the bortezomib combination.